Ecological disturbances in intestinal microflora caused by clinafloxacin, an extended-spectrum quinolone

Infection

Volumn 28, Issue 5, 2000, Pages 272-277

  Oh, H ^a   Nord, C E ^a   Barkholt, L ^a   Hedberg, M ^a   Edlund, C ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SÖDERTÖRN UNIVERSITY   (Sweden)

Author keywords

Clinafloxacin; Intestinal microflora; Quinolones

Indexed keywords

CLINAFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COUNT; BACTEROIDES; CORRELATION FUNCTION; DRUG EFFECT; DRUG FECES LEVEL; FECES ANALYSIS; FEMALE; HUMAN; HUMAN EXPERIMENT; INTESTINE FLORA; MALE; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN;

ADMINISTRATION, ORAL; ADULT; ANTI-INFECTIVE AGENTS, FLUOROQUINOLONE; BACTEROIDES; DRUG RESISTANCE, MICROBIAL; FECES; FEMALE; HUMAN; INTESTINES; MALE; MICROBIAL SENSITIVITY TESTS; TIME FACTORS;

EID: 0033770497     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s150100070018     Document Type: Article

References (30)

1. In-vitro activity of clinafloxacin, trovafloxacin and ciprofloxacin
2. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC and parE loci
3. Activity of quinolones against viridans group streptococci isolated from blood cultures of patients with haematological malignancy
4. Comparative activities of clinafloxacin against gram-positive and -negative bacteria
5. Bay 12-8039, a new 8-methoxy-quimolone: Comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria
6. In vitro activity of clinafloxacin against contemporary clinical bacterial isolates from 10 North American centers
7. In vitro activities of six fluoroquinolones against Canadian isolates of vancomycin-resistant Enterococcus species
8. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: Overexpression, purification and differential inhibition by fluoroquinolones
9. In-vitro activities of 16 non-beta-lactam antibiotics against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae
10. In vitro activity of clinafloxacin against fluoroquinolone resistant Spanish clinical isolates
11. Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins
12. Ecological impact of antimicrobial agents on human intestinal microflora
13. Colonization pattern of the digestive tract by potentially pathogenic microorganisms: Colonization controlling mechanisms and consequences for antibiotic treatment
14. Comparative effects of levofloxacin and ofloxacin on the normal oral and intestinal microflora
15. Effects of quinolones on intestinal ecology
16. Ecological effect of gatifloxacin on the normal intestinal microflora
17. Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microflora
18. Pharmacokinetics, pharmacodynamics and tolerability profile of clinafloxacin
19. Influence of gender on the pharmacokinetics and pharmacodynamics of drugs
20. Relationships among liver and kidney volumes, lean body mass and drug clearance
21. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man
22. Bacterial resistance to fluoroquinolones: Lessons to be learned
23. GyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae
24. Alteration in the gyrA subunit of DNA gyrase and the parC subunit of DNA topoisomerase IV in quinolone-resistant clinical isolates of Staphylococcus epidermidis
25. Molecular cloning of the gyrA and gyrB genes of Bacteroides fragilis encoding DNA gyrase
26. Resistance gene transfer in anaerobes: New insights, new problems